Low-molecular-weight heparins: Mechanisms, trials, and role in contemporary interventional medicine

American Journal of Cardiovascular Drugs

Volumn 8, Issue 1, 2008, Pages 15-25

  Canales, John F ^a   Ferguson, James J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b St Luke's Episcopal Hospital   (United States)

Author keywords

Antithrombotics, therapeutic use; Cardiovascular disorders, treatment; Dalteparin sodium, therapeutic use; Enoxaparin sodium, therapeutic use; Fondaparinux sodium, therapeutic use; GPIIb IIIa antagonists, therapeutic use; Heparins, therapeutic use

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; STREPTOKINASE; TENECTEPLASE; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBOPLASTIN; TIROFIBAN; UROKINASE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FIBRIN CLOT; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NON ST ELEVATION MYOCARDIAL INFARCTION; OSTEOLYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION;

EID: 39749170277     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808010-00003     Document Type: Review

References (51)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
3. de Feyter PJ, van den Brand M, Serruys PW, et al. Early angiography after myocardial infarction: what have we learned? Am Heart J 1985; 109: 194-9
4. Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418-27
5. Ardissino D, Merlini PA, Arlens R, et al. Tissue factor in human coronary athersclerotic plaques. Clin Chim Acta 2000; 291: 235-40
6. Weitz JI. Activation of blood coagulation by plaque rupture: mechanisms and prevention. Am J Cardiol 1995; 75: 18B-22B
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight segheparin with unfractionated heparin for unstable coronary disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-q wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52
8. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results from the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601
9. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable unstable angina/non-Q-wave myocardial infarction: TIMI 11B/ESSENCE meta-analysis. Circulation 1999; 100: 1602-8
10. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of of patients with unstable angina and non-ST-elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002; 40: 1366-74
11. Weitz JI. Low molecular weight heparins [published erratum appears in N Engl J Med 1997; 337: 1567]. N Engl J Med 1997; 337: 688-98
12. Jordan RE, Oosta GM, Gardner WT, et al. The kinetics of hemostatic enzymeantithrombin interactions in the presence of low molecular weight heparin [abstract]. J Biol Chem 1980; 255: 10081
13. Young E, Wells P, Holloway S, et al. Ex vivo and in-vitro evidence that low molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparins. Thromb Haemost 1994; 71: 300-4
14. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin [abstract]. N Engl J Med 1995; 332: 1330
15. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro [abstract]. Thromb Haemost 1998; 80: 413
16. Klein W, Buchwald A, Hillis SE, for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC) [abstract]. Circulation 1997; 96: 61
17. The FRAX. I.S. investigators. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62
18. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347: 561-8
19. Wallentin L, Husted S, Kontny F, et al. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study [abstract]. Lancet 1999; 354: 701
20. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002; 144: 470-7
21. Ferguson JJ, Antman EM, Bates ER, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE 3) study. Am Heart J 2003; 146: 628-34
22. Goodman SG, Fitchett D, Armstrong PW, et al. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-44
23. Ferguson JJ. Califf RM, Antman EM, et al., SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54
24. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: the A phase of the randomised Aggrastat to Zocor (A to Z) trial. JAMA 2004; 292: 55-64
25. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103: 658-63
26. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI(PEPCI) study. Catheter Cardiovasc Interv 2004; 61: 163-70
27. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy results from the A phase of the A-to-Z trial. Eur Heart J 2004; 25: 1688-94
28. Yusuf S, Mehta SR, Chrolavicius S, et al., for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-76
29. Buller CE, Pate GE, Armstrong PW, et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 2006; 22: 511-5
30. Welsh RC, Gordon P, Westerhout CM, et al. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. Catheter Cardiovasc Interv 2007; 70: 341-8
31. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391-5
32. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40: 1943-50
33. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention (NICE 1). J Invasive Cardiol 2001; 13: 272-8
34. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention (NICE 4). J Invasive Cardiol 2001; 13: 272-8
35. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41 (1): 20-5
36. Natarajan MK, Velianou JL, Turpie AG, et al. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J 2006; 151: 175e1-e6
37. Montalescot G, White HD, Gallo R, et al., on behalf of the STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-17
38. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997; 30: 962-9
39. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction: a pilot study: Biochemical Markers in Acute Coronary Syndrome (BI-OMACS II). J Am Coll Cardiol 1999; 33: 627-33
40. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-tPA (alteplase) for improvement of coronary artery patency in acute myocardial infarction: the ASSENT Plus study. Eur Heart J 2003; 24: 897-908
41. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with use of low molecular weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-8
42. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52
43. The Assessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT 3) investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT 3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605-13
44. Antman E, Louwerenburg H, Baars H, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE Thrombolysis In Myocardial Infarction Trial (TIMI) 23 Trial. Circulation 2002; 105: 1642-9
45. Simoons ML, Alonso A, Krzeminska-Pakula M, et al. Early ST-segment elevation resolution: predictor of outcome and angiographic patency in patients with acute myocardial infarction: results of the AMI-SK study [abstract]. Eur Heart J 2001; 22: 13
46. Wallentin L, Goldstein P, Armstrong P, et al. Efficacy and safety of tenecteplase in combination with the low molecular weight heparin enoxaparin or unfractionatpharmacotherapy ed heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT 3 PLUS) randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-42
47. Cohen M, Gensini G, Maritz F, et al., for the TETAMI Investigators. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofoban versus placebo in the treatment of acute ST elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003; 42: 1348-56
48. Yusuf S, Mehta SR, Xie C, et al. The CREATE Trial Group Investigators. Effects of reviparin, a low molecular weight heparin, on mortality, reinfarction, and stroke in patients with acute myocardial infarction presenting with ST elevation. JAMA 2005; 293: 427-35
49. Antman E, Morrow D, McCabe C, et al., for the ExTRACT TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST elevation myocardial infarction. N Engl J Med 2006; 354: 1477-88
50. Gibson M, for the PCI-ExTRACT TIMI 25 Investigators. Percutaneous coronary intervention outcomes among patients treated with enoxaparin versus unfractionated heparin following fibrinolytic administration for ST elevation myocardial infarction. World Congress of Cardiology 2006; 2006 Sep 2-4; Barcelona
51. Peterson J, Mahaffey K, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89-96